Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

ensartinib MeSH Supplementary Concept Data 2025


MeSH Supplementary
ensartinib
Unique ID
C000629294
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000629294
Entry Term(s)
6-amino-5-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide
X-396
Pharm Action
Antineoplastic Agents
Protein Kinase Inhibitors
Registry Numbers
SMA5ZS5B22
Heading Mapped to
*Piperazines
*Pyridazines
Frequency
25
Note
anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive non-small-cell lung cancer
Source
Future Oncol. 2018 Aug;14(18):1781-1787.
Date of Entry
2018/12/14
Revision Date
2018/12/14
ensartinib Preferred
X-396 Narrower
page delivered in 0.003s